Filament Health Corp CEO Ben Lightburn tells Proactive the Vancouver-Canada-based natural psychedelic drug discovery company has been given the green light by the FDA and is ready to begin its clinical trial using naturally-sourced psychedelic substances.
Lightburn says the Phase 1 trial is led by the Translational Psychedelic Research Program at the University of California San Francisco. The group expects to begin enrolling patients soon, with data expected in the 2022/2023 timeframe.